SCHEMBL2967131

SCHEMBL2967131

COCCCN1CCN(Cc2ccc(-n3nc(I)c4c(N)ncnc43)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.39
▸ MAP4K4 O95819 2/20 0.39
▸ ACHE P22303 1/20 0.37
▸ RAD52 P43351 1/20 0.37
▸ EGFR P00533 5/20 0.37
▸ ERBB2 P04626 4/20 0.37
▸ IGF1R P08069 4/20 0.37
▸ ERBB3 P21860 2/20 0.37
▸ ERBB4 Q15303 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PDE1B Q01064 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ NTSR1 P30989 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13201536 0.75 SRC (0.47) MAP4K4EGFRKDM4EMAPK1SRC
SCHEMBL2960099 0.74 SRC (0.55) MAP4K4EGFRERBB2IGF1RERBB3
SCHEMBL2965844 0.73 EGFR (0.48) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL2962536 0.69 MAP4K4 (0.41) MAP4K4MAPK1PIK3CDSRCFGFR2
SCHEMBL4818639 0.69 SRC (0.59) MAP4K4EGFRMAPK1SRC
SCHEMBL24096870 0.69 SRC (0.45) MAP4K4EGFRMAPK1PIK3CDSRC
SCHEMBL4825100 0.69 SRC (0.56) MAP4K4MAPK1PIK3CDSRCFGFR2
SCHEMBL24096486 0.68 SRC (0.50) MAP4K4EGFRALDH1A1KDM4EMAPK1
SCHEMBL5804464 0.68 BTK (0.60) MAP4K4EGFRERBB2ERBB4PIK3CD
SCHEMBL2969443 0.67 SRC (0.46) MAP4K4EGFRKDM4EMAPK1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 HRH3 2957/4885MAP4K4 42/4885ACHE 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback